Clinical management of metastatic colorectal cancer in the era of precision medicine

F Ciardiello, D Ciardiello, G Martini… - CA: a cancer journal …, 2022 - Wiley Online Library
Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …

Increasing incidence of early-onset colorectal cancer

FA Sinicrope - New England Journal of Medicine, 2022 - Mass Medical Soc
Early-Onset Colorectal Cancer Early-onset disease (at< 50 years of age) accounts for 10%
of colorectal cancer cases, and the incidence is increasing, particularly in high-income …

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

A Cervantes, R Adam, S Roselló, D Arnold… - Annals of …, 2023 - annalsofoncology.org
Colorectal cancer (CRC) is the third most common cancer worldwide, with 1.1 million new
cases per year, and is the second leading cause of cancer death. 1 CRC occurs more …

PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer

A Cercek, M Lumish, J Sinopoli, J Weiss… - … England Journal of …, 2022 - Mass Medical Soc
Background Neoadjuvant chemotherapy and radiation followed by surgical resection of the
rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is …

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a …

LA Diaz, KK Shiu, TW Kim, BV Jensen… - The Lancet …, 2022 - thelancet.com
Background Pembrolizumab has shown improved progression-free survival versus
chemotherapy in patients with newly diagnosed microsatellite instability-high or mismatch …

Mechanisms driving the immunoregulatory function of cancer cells

A van Weverwijk, KE de Visser - Nature Reviews Cancer, 2023 - nature.com
Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

Immunotherapies for hepatocellular carcinoma

JM Llovet, F Castet, M Heikenwalder… - Nature reviews Clinical …, 2022 - nature.com
Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

The foundations of immune checkpoint blockade and the ipilimumab approval decennial

AJ Korman, SC Garrett-Thomson… - Nature Reviews Drug …, 2022 - nature.com
Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …

Young-onset colorectal cancer

MCW Spaander, AG Zauber, S Syngal… - Nature reviews Disease …, 2023 - nature.com
In the past decades the incidence of colorectal cancer (CRC) in people under the age of 50
years has increased, which is referred to as early-onset CRC or young-onset CRC (YO …

Treatment of metastatic colorectal cancer: ASCO guideline

VK Morris, EB Kennedy, NN Baxter… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE To develop recommendations for treatment of patients with metastatic colorectal
cancer (mCRC). METHODS ASCO convened an Expert Panel to conduct a systematic …